Login / Signup
Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC.
Fumio Imamura
Takako Inoue
Kei Kunimasa
Aki Kubota
Hanako Kuhara
Motohiro Tamiya
Kazumi Nishino
Madoka Kimura
Kika Kuno
Hayato Kawachi
Toru Kumagai
Published in:
Lung cancer management (2020)
Switch use of osimertinib seemed to produce improved efficacy for patients with activating EGFR mutations, because of the lack of patient selection via T790M.
Keyphrases
</>
small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
brain metastases
case report
signaling pathway